Help
RSS
API
Feed
Maltego
Contact
Domain > accuronix.com
×
Welcome!
Right click nodes and scroll the mouse to navigate the graph.
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
Whois
Property
Value
NameServer
NS2.SITEGROUND200.COM
Created
2015-04-03 00:00:00
Changed
2016-03-19 00:00:00
Expires
2017-04-03 00:00:00
Registrar
TUCOWS DOMAINS INC.
DNS Resolutions
Date
IP Address
2024-09-12
104.21.6.101
(
ClassC
)
2025-01-19
172.67.134.181
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Wed, 20 Mar 2024 07:53:46 GMTContent-Type: text/html; charsetiso-8859-1Transfer-Encoding: chunkedConnection: keep-aliveLocation: https://accuronix.com/Cache-Control !DOCTYPE HTML PUBLIC -//IETF//DTD HTML 2.0//EN>html>head>title>301 Moved Permanently/title>/head>body>h1>Moved Permanently/h1>p>The document has moved a hrefhttps://accuronix.com/>here/a>./p>hr>address>Apache/2.4.58 (Debian) Server at accuronix.com Port 80/address>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Wed, 20 Mar 2024 07:53:46 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveVary: X-Forwarded-Proto,Accept-EncodingLast-Modified: Thu, 14 Mar !DOCTYPE html>html langen-US>head itemscope itemtypehttps://schema.org/WebSite>meta charsetUTF-8 />meta nameviewport contentwidthdevice-width, initial-scale1 />title>Accuronix - Developing novel cancer therapies/title>meta namedescription contentAccuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk.>meta namerobots contentindex, follow>meta namegooglebot contentindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1>meta namebingbot contentindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1>link relcanonical hrefhttps://accuronix.com/>script typeapplication/ld+json>{@context:https://schema.org,@type:WebSite,name:Accuronix - Developing novel cancer therapies,alternateName:Accuronix,description:Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk.,url:https://accuronix.com,potentialAction:{@type:SearchAction,target:{@type:EntryPoint,urlTemplate:https://accuronix.com/?s{search_term_string}},query-input:required namesearch_term_string}}/script>meta propertyog:url contenthttps://accuronix.com/>meta propertyog:site_name contentAccuronix>meta propertyog:locale contenten_US>meta propertyog:type contentwebsite>meta propertyog:title contentAccuronix - Developing novel cancer therapies>meta propertyog:description contentAccuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk.>meta propertyog:image contenthttps://accuronix.com/wp-content/uploads/2016/04/platform-technology.jpg>meta propertyog:image:secure_url contenthttps://accuronix.com/wp-content/uploads/2016/04/platform-technology.jpg>meta propertyog:image:width content400>meta propertyog:image:height content400>meta propertyog:image:alt contentPlatform Technology>meta propertyfb:pages content>meta propertyfb:admins content>meta propertyfb
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]